{"id":157674,"date":"2019-12-14T09:16:24","date_gmt":"2019-12-14T14:16:24","guid":{"rendered":"https:\/\/www.bu.edu\/sph\/?p=157674"},"modified":"2020-09-17T10:19:59","modified_gmt":"2020-09-17T14:19:59","slug":"the-pain-gap","status":"publish","type":"bu-article","link":"https:\/\/www.bu.edu\/sph\/news\/articles\/2019\/the-pain-gap\/","title":{"rendered":"The Pain Gap"},"content":{"rendered":"\n<div class=\"wp-prepress-component-metabar sphnews-prepress-layout-metabar\">\n\t<div class=\"wp-prepress-component-metabar-wrapper\">\n\t\t\t\t\t<div class=\"wp-prepress-component-metabar-date\">December 14, 2019<\/div>\n\t\t\n\t\t\t\t<div class=\"wp-prepress-component-metabar-credits\">\n\t\t\t\t\t<\/div>\n\t\t<div class=\"wp-prepress-component-metabar-share js-bu-prepress-share-tools\">\n\t\t\t<span class=\"icon-twitter\"><span>Twitter<\/span><\/span>\n\t\t\t<span class=\"icon-facebook\"><span>Facebook<\/span><\/span>\n\t\t\t<span class=\"icon-action\"><\/span>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<p><img loading=\"lazy\" src=\"\/sph\/files\/2019\/12\/prescription-medicine-blister-packaging-400x241-e1576187327990.png\" alt=\"\" class=\"alignleft size-full wp-image-157690\" width=\"400\" height=\"241\" \/><\/p>\n<p class=\"p1\"><span class=\"s1\">Before the opioid crisis, there was the Vioxx scandal. <\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">When Vioxx (rofecoxib) came on the market in 1999, it was part of a new class of anti-inflammatory drugs called COX-2 inhibitors, painkillers without the gastrointestinal side effects of other NSAIDS such as aspirin and ibuprofen, making them promising for chronic pain management. But in 2004, Merck withdrew the drug amid <a href=\"https:\/\/www.npr.org\/2007\/11\/10\/5470430\/timeline-the-rise-and-fall-of-vioxx\" target=\"_blank\" rel=\"noopener noreferrer\"><span class=\"s2\">mounting evidence<\/span><\/a><span class=\"s2\"> <\/span><span class=\"s2\">that long-term Vioxx use significantly raised the risk of heart attack and stroke (and that Merck researchers may have covered up data<\/span>). According to <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(05)17864-7\/fulltext#secd750494e1517\" target=\"_blank\" rel=\"noopener noreferrer\"><span class=\"s2\">research later published in <i>The Lancet<\/i><\/span><\/a>, Vioxx caused up to 140,000 heart attacks in the US, killing 38,000 people.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">After the Vioxx scandal, other (safer) COX-2 inhibitors also fell out of favor, and prescriptions for high-dose NSAIDS declined across the board. <\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Opioids filled the gap.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">That\u2019s according to a new School of Public Health study published in <a href=\"http:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/10.1001\/jamanetworkopen.2019.17228?utm_source=For_The_Media&amp;utm_medium=referral&amp;utm_campaign=ftm_links&amp;utm_term=121119\" target=\"_blank\" rel=\"noopener noreferrer\"><span class=\"s2\"><i>JAMA Network Open<\/i><\/span><\/a>, the first study to suggest that this early-2000s decline in NSAID prescriptions for chronic pain contributed to the rise of opioids, and the deadly opioid epidemic still raging today. <\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">\u201cWe see almost a mirror image, where opioid prescribing is going up at the same time that non-opioid analgesic prescribing is going down,\u201d says lead study author <a href=\"https:\/\/www.bu.edu\/sph\/profile\/andrew-stokes\/\"><span class=\"s2\">Andrew Stokes<\/span><\/a>, assistant professor of global health. <\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">And the Vioxx scandal is right at the center of it, says study senior author <a href=\"https:\/\/www.bu.edu\/sph\/profile\/tuhina-neogi\/\"><span class=\"s2\">Tuhina Neogi<\/span><\/a>, professor of epidemiology at SPH, professor of rheumatology at the School of Medicine, and chief of rheumatology at Boston Medical Center. \u201cWe realized that the point at which increasing opioid prescriptions crossed over with the decrease in non-opioid prescriptions occurred when the cardiovascular risks of COX-2 inhibitors led to Vioxx coming off the market,\u201d she says.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">But as recognition of the opioid crisis has now led to the decline of another kind of prescription painkiller, what is taking its place? Likely nothing, Stokes says. <\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">From 2013 to 2016, the researchers saw an 11-percent decrease in <i>all<\/i> painkiller prescriptions in the study population (7,256 adults with musculoskeletal chronic pain issues from 1999 to 2016). \u201cThe drop across the board in opioid and non-opioid analgesic use suggests either that people are increasingly seeking out and accessing other therapies like physical therapy,\u201d Stokes says, \u201cor, more likely, there is just an increase in unmet need for pain relief.\u201d<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">People with lower socioeconomic status had the steepest drop in prescriptions, the study found\u2014and Stokes points out that these are the populations least likely to have access to such non-pharmaceutical therapies. <\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">\u201cThere\u2019s so much talk right now about transitioning people away from opioids,\u201d says study co-author <a href=\"https:\/\/www.bu.edu\/sph\/profile\/dielle-lundberg\/\"><span class=\"s2\">Dielle Lundberg<\/span><\/a> (SPH\u201919), a research fellow in the Department of Global Health. \u201cBut if that\u2019s happening without considering the barriers to non-pharmacologic treatments, there may be a significant problem of under-treatment of pain.\u201d<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">While the study found a decline in opioid prescriptions for racial\/ethnic minorities, it wasn\u2019t a very large drop. \u201cThe existing literature shows longstanding racial bias in opioid prescribing,\u201d Stokes explains, with <a href=\"https:\/\/www.pnas.org\/content\/early\/2016\/03\/30\/1516047113.abstract\" target=\"_blank\" rel=\"noopener noreferrer\"><span class=\"s2\">doctors particularly distrusting black patients and believing that they experience less pain<\/span><\/a>. The new study of people with chronic pain supports this, showing that black patients were particularly unlikely to be prescribed opioids at any point in the observed period. There wasn\u2019t a significant drop, in other words, because there was likely already unmet need.\u00a0<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">The pain relief gap revealed by this study is not news to those who live in it, Lundberg notes. \u201cA lot of these issues have been previously voiced by activists with chronic pain,\u201d they say. \u201cBut most of their work and advocacy has been qualitative, which has caused some to question the generalizability of their reports.&#8221; The researchers hope this study adds quantitative evidence that will raise the profile of this issue.\u00a0<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">None of this is to diminish the significant toll of the opioid epidemic, or claim that opioids have not been aggressively marketed and over-prescribed, Lundberg says. \u201cIt\u2019s an \u2018and\u2019 situation.\u201d<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Stokes says under-treatment can also be deadly. \u201cThere\u2019s concerning literature that people with unmet need for pain relief have higher rates of suicidal ideation and completed suicide,\u201d he says, \u201cas well as seeking out other sources of pain relief, such as fentanyl or heroin.\u201d In other words, under-prescribing opioids can still lead to opioid deaths.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">\u201cWe need to ensure that our response to the opioid crisis does not leave people living with chronic pain behind,\u201d Stokes says.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">The study was supported by the Robert Wood Johnson Foundation. The other co-authors were: alum Kaitlyn Berry (SPH\u201917), now of the University of Minnesota School of Public Health; and Katherine Hempstead of the Robert Wood Johnson Foundation.<\/span><\/p>\n<p>\u2014<a href=\"mailto:msamu@bu.edu\" target=\"_blank\" rel=\"noopener noreferrer\"><em>Michelle Samuels<\/em><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Concerns about other painkillers may have contributed to the opioid crisis. As opioid prescriptions now decline, people living with chronic pain likely face significant unmet need for relief.<\/p>\n","protected":false},"author":10989,"featured_media":157690,"comment_status":"closed","ping_status":"open","template":"","meta":{"bu_prepress_billboard":"","_bu_prepress_primary_term":"","_bu_prepress_primary_term_manual":""},"tags":[2522,2413,2621,2137,2452,1895,1781,1735],"bu-publication":[3516],"sphnews-article-category":[3519,3530,3531,3532,3540],"sphnews-topic":[],"bu_edition":[],"media_type":[],"profile_tax":[1402,2799],"_links":{"self":[{"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/bu-article\/157674"}],"collection":[{"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/bu-article"}],"about":[{"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/types\/bu-article"}],"author":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/users\/10989"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/comments?post=157674"}],"version-history":[{"count":6,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/bu-article\/157674\/revisions"}],"predecessor-version":[{"id":172956,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/bu-article\/157674\/revisions\/172956"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/media\/157690"}],"wp:attachment":[{"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/media?parent=157674"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/tags?post=157674"},{"taxonomy":"bu-publication","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/bu-publication?post=157674"},{"taxonomy":"sphnews-article-category","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/sphnews-article-category?post=157674"},{"taxonomy":"sphnews-topic","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/sphnews-topic?post=157674"},{"taxonomy":"bu_edition","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/bu_edition?post=157674"},{"taxonomy":"media_type","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/media_type?post=157674"},{"taxonomy":"profile_tax","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/profile_tax?post=157674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}